Psychopharmacology of pediatric bipolar disorder

Expert Review of Neurotherapeutics

Volumn 10, Issue 7, 2010, Pages 1053-1088

  Hamrin, Vanya ^a   Iennaco, Joanne Desanto ^a  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

antipsychotics; mania; mood stabilizers; pediatric; pediatric bipolar disorder; psychopharmacological treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TETRACYCLINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE; PSYCHOTROPIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; AGGRESSIVENESS; AGITATION; AKATHISIA; ALOPECIA; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BALANCE DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BLOOD DYSCRASIA; BLURRED VISION; CARDIOVASCULAR SYMPTOM; CHILD PSYCHIATRY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON COLD SYMPTOM; COMORBIDITY; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; CREATININE BLOOD LEVEL; CYCLOTHYMIA; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSTHYMIA; DYSTONIA; EDEMA; ENURESIS; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FLU LIKE SYNDROME; FLUENCY DISORDER; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HOSTILITY; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; HYPOMANIA; HYPOTHYROIDISM; INCREASED APPETITE; INFECTION; INFLUENZA; INSOMNIA; IRRITABILITY; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOCYTOSIS; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR DEPRESSION; MALE TYPE ALOPECIA; MENTAL DISEASE; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE RIGIDITY; MUSCLE TWITCH; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NEUROLOGIC DISEASE; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; POLYDIPSIA; POLYURIA; PREVALENCE; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOLOGY; QT INTERVAL; RECURRENCE RISK; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SODIUM BLOOD LEVEL; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STIFF NECK; STOMACH PAIN; SUICIDAL IDEATION; SYNCOPE; TARDIVE DYSKINESIA; THROMBOCYTE COUNT; TINNITUS; TREMOR; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT GAIN; ADOLESCENT; CHILD;

ADOLESCENT; BIPOLAR DISORDER; CHILD; HUMANS; PSYCHOTROPIC DRUGS;

EID: 77954201129     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.86     Document Type: Review

References (102)

1. Birmaher B, Axelson D, Goldstein B. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: The course and outcome of bipolar youth (COBY) study. Am. J. Psychiatry 166 (7), 795-802 (2009).
2. Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J. Psychiatr. Res. 37, 291-303 (2003).
3. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J. Clin. Psychiatry 68, 789-795 (2007).
4. Geller B, Tillman R, Craney J, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch. Gen. Psychiatry 61(5), 459-467 (2004). (Pubitemid 38620844)
5. Lofthouse N, Fridstad M. Psychosocial interventions for children with early-onset bipolar spectrum disorder. Clin. Child Fam. Psychol. Rev. 21, 71-89 (2004).
6. Wozniak J, Beiderman, J, Kiely K et al. Manic-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J. Am. Acad. Child Adolesc. Psychiatry 34, 867-876 (1995).
7. Perlis R, Miyahara S, Marangell LB et al. Long-term implications of early onset in bipolar disorder: data from the frst 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 55, 875-881 (2004).
8. Kogan J, Otto M, Bauer M et al. Demographic and diagnostic characteristics of the frst 1000 patients enrolled in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Bipolar Disord. 6(6), 460-469 (2004).
9. Youngstrom EA, Birhamer B, Findling RL. Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis. Bipolar Disord. 10, 194-214 (2008).
10. Baroni A, Lunsford J, Luckenbaugh D. Towbin K, Leibenluft E. Practitioner review: the assessment of bipolar disorder in children and adolescents. J. Child Psychol. Psychiatry 50, 203-215 (2008).
11. Bhangoo RK, Lowe CH, Myers FS et al. Medication use in children and adolescents treated in the community for bipolar disorder. J. Child Adolesc. Psychopharmacol. 13, 515-522 (2003).
12. Hellander M. Lithium Testing In Children: A Public Health Necessity. Testimony to the US FDA, DC, USA (2002).
13. Youngstrom E, Duax J. Evidence-based assessment of pediatric bipolar disorder, part I: base rate and family history. J. Am. Acad. Child Adolesc. Psychiatry 44(7), 712-717 (2005).
14. Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. J. Am. Acad. Child Adolesc. Psychiatry, 36, 1168-1176 (1997).
15. Findling RL, Gracious BL, McNamara NK et al. Rapid, continuous cycling and psychiatric comorbidity in pediatric bipolar I disorder. Bipolar Disord. 3, 202-210 (2001).
16. Biederman J, Mick E, Spencer TJ, Wilens TE, Faraone S V. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J. Child Adolesc. Psychopharmacol. 10, 185-192 (2000).
17. Moreno C, Laje G, Blanco C, Jiang H, Schmidt A, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry 64, 1032-1039 (2007).
18. Coletti, D. Leigh E, Gallelli K, Kafantaris V. Patterns of adherence to treatments in adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 15(6), 913-917 (2005).
19. Lewinsohn P, Klein D, Seeley J. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J. Am. Acad. Child Adolesc. Psychiatry 34(4), 454-463 (1995).
20. Orvashel H, Puig-Antich J, Chambers WJ, Tabrizi MA, Johnson R. Retrospective assessment of prepubertal major depression the Kiddie-SADS-E. J. Am. Acad. Child Psychiatry 21, 392-397 (1982).
21. Youngstrom E, Findling R, Calabrese J et al. Comparing the diagnostic accuracy of six potential screening instruments for bipolar disorder in youth ages 5 to 17 years. J. Am. Acad. Child Adolesc. Psychiatry 43(7), 847-858 (2004).
22. Youngstrom E, Duax J. Evidence-based assessment of pediatric bipolar disorder, part I: base rate and family history. J. Am. Acad. Child Adolesc. Psychiatry 44(7), 712-717 (2005).
23. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirshfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar member. J. Affect. Disord. 31, 281-294 (1994).
24. Soutullo CA, Chang, KD, Diez-Suarez A, Figueroa-Quintana A, Escamilla-Canales I. Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disord. 7, 497-506 (2005).
25. Bschor T, Lweitza U, Sasse J, Adli M, Koberle U, Bauer M. Lithium augmentation in treatment resistant depression. Clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 36(3), S230-S234 (2003).
26. Manji H, Lenox K. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry 46(10), 1328-1351 (1999).
27. Geller B, Cooper T, Sun K et al. Double blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependence. J. Am. Acad. Child Adolesc. Psychiatry 37, 171-178 (1998).
28. Kafantaris V, Coletti D, Dicker R, Padula G, Kane J. Lithium treatment of acute mania in adolescents: a large open trial. J. Am. Acad. Child Adolesc. Psychiatry 42, 1038-1045 (2003).
29. Guy W (Ed.). ECDEU Assessment for Psychopharmacology. Revised Edition. NIMH Publication, MD, USA (1976).
30. Young RC, Boggs KT, Ziegler VE, Meyers DA. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 429-435 (1978).
31. Kafantaris V, Coletti D, Dicker R et al. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J. Am. Acad. Child Adolesc. Psychiatry 43(8), 984-993 (2004).
32. Strober M, DeAntonio M, Schmidy-Lackner S, Freeman R, Lampert C, Diamond J. Early childhood attention defcit hyperactivity disorder predicts poorer response to acute lithium therapy in adolescent mania. J. Affect. Disord. 51, 148-151 (1998).
33. Patel N, Delbello M, Bryan H et al. Open-label lithium for the treatment of adolescents with bipolar depression. J. Am. Acad. Child Adolesc. Psychiatry 45(3), 289-297 (2006).
34. Pozanaski, E, Freeman IN, Mokros H. The Children's Depression Rating Scale Revised. Pscyhopharm. Bull. 21, 979-989 (1985).
35. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defning clinical phenotypes of juvenile mania. Am. J, Psychiatry 160, 430-437 (2003). (Pubitemid 41094250)
36. Dickstein DP, Towbin KE, Van Der Veen JW et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J. Child Adolesc Psychopharmacol. 19, 61-73 (2009).
37. Scahill L, Farkas L, Hamrin V. Lithium in children and adolescents. J. Child Adolesc. Psych. Nurs. 14(2), 89-93 (2001).
38. Stahl S. Stahl's Essential Psychopharmacology: Neuroscientifc Basis and Practical Applications. 3rd Edition. Cambridge University Press, Cambridge, UK, 672 (2008).
39. Wagner KD, Redden L, Kowatch RA et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 48(5), 519-532 (2009).
40. Wagner K, Kowatch R, Emslie G et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am. J. Psychiatry 163, 1179-1186 (2006).
41. Delbello M, Findling R, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44(6), 539-547 (2005).
42. Joshi G, Wozniak J, Mick E et al. A prospective open-label trial of extended release carbamazepine monotherapy in children with bipolar disorder. J. Child Adolesc. Psychopharmacol. 20(1), 7-14. (2010).
43. Papatheodorou G, Kutcher SP, Katic M, Szalai JP. The effcacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults; an open clinical trial. J. Clin. Pscyhopharmacol. 15(2), 110-116 (1995).
44. Wagner K, Weller E, Carlson G et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 41, 1224-1230 (2002). (Pubitemid 38338042)
45. Findling RL, Frazier T W, Youngstrom EA et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J. Clin. Psychiatry 68, 781-788 (2007).
46. Chang K, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J. Clin. Psychiatry 64(8), 936-942 (2003).
47. Redden L, DelBello M, Wagner K et al. Long-term safety of divalproex extended release in children and adolescents with bipolar I disorder. J. Child Adolesc. Psychopharmacol. 19(1), 83-89 (2009).
48. Davanzo, P, Gunderson B, Belin T et al. Mood stabilizers in hospitalized children with bipolar disorder: a retrospective review. Psychiatry Clin. Neurosci. 57(5), 504-513 (2003).
49. Kowatch R, Suppes T, Carmody T et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 39, 713-720 (2000).
50. Pavuluri MN, Henry, DB, Carbray JA, Naylor M W, Janicak PG. Divalproex sodium for pediatric mixed mania: a 6-month prospective trial. Bipolar Disord. 7, 266-273 (2005).
51. Findling R, McNamara N, Gracious E et al. Combination lithium and divalproex sodium in pediatric bipolarity. J. Am. Acad. Child Adolesc. Psychiatry, 42, 895-901 (2005).
52. Goldsmith DR, Wagstaff AH, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 63, 2029-2050 (2003).
53. Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney JA. Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol. 19(1), 75-82 (2009).
54. Chang K, Saxena K, Howe M. An open label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J. Am. Acad. Child Adolesc. Psychiatry 45, 298-304 (2006).
55. Biederman J, Joshi G, Mick E et al. A prospective open label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci. Ther. 16, 91-102 (2010).
56. Joffe H, Cohen L, Suppes T et al. Valproate is associated with new onset oligoamenorrhea, with hyperandogenism in women with bipolar disorder. Biol. Psychiatry 59 (11), 1078-1084 (2006).
57. Kuehn B. FDA panel OKs 3 antipsychotic drugs for the pediatric use, cautions against overuse. JAMA 302(8), 833-834 (2009).
58. Tohen M, Kryzhanovskaya L, Carlson G et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am. J. Psychiatry 164(10), 1547-1556 (2007).
59. Haas M, DelBello MP, Pandina G et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 11, 687-700 (2009).
60. Findling RL, Nyilas M, Forbes RA et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 70(10), 1441-1451 (2009).
61. Tramontina S, Zeni C, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-defcit/hyperactivity disorder: a pilot randomized clinical trial. J. Clin. Psychiatry 70(5), 756-764 (2009).
62. DelBello MP, Chang K, Welge JA et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 11, 483-493 (2009).
63. DelBello MP, Cecil KM, Adler CM, Daniels JP, Strakowski SM. Neurochemical effects of olanzapine in frst-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 31, 1264-1273 (2006).
64. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol. 19(5), 539-545 (2009).
65. Frazier JA, Biederman J, Tohen M et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 11(3), 239-250 (2001).
66. Biederman J, Mick, E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 15(2), 311-317 (2005). (Pubitemid 40734110)
67. Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr. Dis. Treat. 4(1), 203-207 (2008).
68. Frazier JA, Meyer MC, Biederman J et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J. Am. Acad. Child Adolesc. Psychiatry 38(8), 960-965 (1999).
69. Durkin JP. Aripiprazole in the treatment of bipolar disorder in children and adolescents. J. Child Adolesc. Psychopharmacol. 14(4), 505-506 (2004).
70. Barzman DH, DelBello MP, Kowatch RA et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J. Child Adolesc. Psychopharmacol. 14(4), 593-600 (2004).
71. Findling RL, Kauffman RE, Sallee FR et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J. Clin. Psychopharmacol. 28, 441-446 (2008).
72. Biederman J, McDonnell MA, Wozniak J et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectrum 10(2), 141-148 (2005).
73. Tramontina S, Zeni C, Pheula GF, de Souza CK, Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid with attention-defcit/hyperactivity disorder: an open clinical trial. CNS Spectrum 12(10), 758-762 (2007).
74. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: A retrospective chart review. J. Child Adolesc. Psychopharmacology 14(3), 405-411 (2004).
75. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry 9, 4 (2009).
76. Biederman J, Mick E, Spencer T, Dougherty M, Aleardi M, Wozniak J. A prospective open-label treatment trial of ziprasidone montherapy in children and adolescents with bipolar disorder. Bipolar Disord. 9, 888-894 (2007). (Pubitemid 350215115)
77. Kowatch RA, Suppes T, Gilfllan SK, Fuentes RM, Grannemann BD, Emslie GJ. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J. Child Adolesc. Psychopharmacol. 5(4), 241-253 (1995).
78. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J. Child Adolesc. Psychopharmacol. 12(2), 93-99 (2002).
79. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J. Child Neurology 20(7), 603-610 (2005).
80. Gibson AP, Crison ML, Mican LM, Fischer C. Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. Int. Clin. Psychopharmacol. 22(2), 101-105 (2007).
81. DelBello MP, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J. Child Adolesc. Psychopharmacol. 18(5), 491-499 (2008).
82. Versavel M, DelBello MP, Ice K, Kowatch R, Keller D, Miceli J. Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia or schizoaffective disorder. Neuropsychopharmacology 30, S122-S123 (2005).
83. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J. Am. Acad. Child Adolesc. Psychiatry 46(6), 687-700 (2007).
84. Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprazidone: a prospective study. J. Am. Acad. Child Adolesc. Psychiatry 44, 73-79 (2005).
85. Klein DJ, Cottingham EM, Sorter M et al. A randomized double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am. J. Psychiatry 163, (12), 2072-2079 (2006).
86. DelBello MP, Lowatch RA, Adler CM et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry 45, 305-313 (2006).
87. Macmillan CM, Whitney JE, Korndorfer SR, Tilley CA, Mrakotsky C, Gonzalez-Heydrich JM. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J. Psychiatr. Pract. 14(3), 160-169 (2008).
88. MacMillan CM, Korndorfer SR, Rao S, Fleisher CA, Mezzacappa E, Gonzalez HJ. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J. Psychiatr. Pract. 12(4), 214-222 (2006).
89. Biederman J, Mick E, Hammerness P et al. Open-label 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder for preschool-age children. Biol. Psychiatry 58(7), 589-594 (2005).
90. Findling R, McNamara N, Gracious B et al. Combination lithium and divalproex sodium in pediatric bipolarity. J. Am. Acad. Child Adolesc. Psychiatry 42(8), (2003).
91. Findling R, McManera N, Stansbrey R et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. J. Am. Acad. Child Adolesc. Psychiatry 45(2), 142-148 (2006).
92. Delbello M, Schwiers M, Rosenberg H, Strakowski S. A double-blind, randomized, placebo-controlled study of quetapine, as adjunctive treatment for adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry 41, 1216-1223 (2002).
93. Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J. Child Adolesc. Psychopharmacol. 16, 336-350 (2006).
94. Pavuluri M, Henry D, Carbray J, Sampson G, Naylor M, Nanicak P. Open label prospective trial of ripseridone in combination with lithium or divalporex sodium in pediatric mania. J. Affect. Disord. 82S, S103-S111 (2004).
95. Chang K, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-defcit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J. Child Adolesc. Psychopharmacol. 19, 547-555 (2009).
96. Scheffer R, Kowatch R, Carmody T, Rush A. Randomized, placebo controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am. J. Psychiatry 162, 58-64 (2005).
97. Baumer F, Howe M, Gallelli, Iorgova-Simeonava D, Hallmayer J, Chang K. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors and the serotonin transporter gene. Biol. Psychiatry 60(9), 1005-1012 (2006).
98. Cicero D, El-Mallakh, R, Holman, J Robertson J. Antidepressant exposure in bipolar children. Psychiatry 66(4), 317-322 (2003).
99. Hamrin V, Scahill L. Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations. Issues Ment. Health Nurs. 26(4) 433-450 (2005).
100. Reinblatt S, DosReis S, Walkup J, Riddle M. Activation adverse events inducted by the selective serotonin reuptake inhibitor fuvoxamine in children and adolescents. J. Child Adolesc. Psychopharmacol. 19(2), 119-126 (2009).
101. Findling R, McNamera N, Youngstrom E et al. A double blind 18 month trial of lithium versus divalproex maintenance treatment in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44(5), 409-417 (2005). (Pubitemid 40559688)
102. Findling R, Frazier J, Kafantaris V et al. The collaborative lithium trials (CoLT): specifc aims, methods, and implementation. Child Adolesc. Psychiatry Ment. Health 2(1), 21 (2008).